Advanced Pancreatic Ductal Adenocarcinoma clinical trials

Explore recruiting advanced pancreatic ductal adenocarcinoma clinical trials.

Recruiting advanced pancreatic ductal adenocarcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Pancreatic Ductal Adenocarcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Standard versus Prolonged Neoadjuvant (Conversion) Chemotherapy to prolong survival of patients with Borderline and Locally Advanced Pancreatic Cancer: a phase III randomized controlled trial

Sweden, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 1b study investigating the association of NP137 with mFOLFIRINOX in locally advanced pancreatic ductal adenocarcinoma LAP NET 1

France

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors

France, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Phase 1/2 Master Protocol for Open-Label, Multi-Centre, Single-Arm Sub-Studies, First in Human Clinical Studies of TCR-T Therapy (Autologous TCR-Modified T-Cell Therapy) Targeting Mutated Kirsten Rat Sarcoma (mutKRAS) Administered in Metastatic or Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Adult Patients with Specific mutKRAS and Human Leukocyte Antigen (HLA) Genotypes

Germany, Denmark, Netherlands, Sweden

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Advanced Pancreatic Ductal Adenocarcinoma trials by city

Advanced Pancreatic Ductal Adenocarcinoma in Toronto Advanced Pancreatic Ductal Adenocarcinoma in Vancouver Advanced Pancreatic Ductal Adenocarcinoma in Montreal Advanced Pancreatic Ductal Adenocarcinoma in Calgary Advanced Pancreatic Ductal Adenocarcinoma in Edmonton Advanced Pancreatic Ductal Adenocarcinoma in Ottawa Advanced Pancreatic Ductal Adenocarcinoma in Winnipeg Advanced Pancreatic Ductal Adenocarcinoma in Quebec City Advanced Pancreatic Ductal Adenocarcinoma in Hamilton Advanced Pancreatic Ductal Adenocarcinoma in Kitchener Advanced Pancreatic Ductal Adenocarcinoma in London Advanced Pancreatic Ductal Adenocarcinoma in Halifax Advanced Pancreatic Ductal Adenocarcinoma in New York Advanced Pancreatic Ductal Adenocarcinoma in Los Angeles Advanced Pancreatic Ductal Adenocarcinoma in Chicago Advanced Pancreatic Ductal Adenocarcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease